Toni Choueiri

Toni Choueiri, M.D., Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute/Brigham and Women’s Hospital and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School is a recognized thought leader in the GU field who has done extensive work in the development of better treatments for patients with RCC. Choueiri is the Co-Leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center and past President of the Medical Staff at Dana-Farber (2016-2018).

Dr. Choueiri works on the development of novel experimental therapies and biomarkers in GU malignancies, including Kidney Cancer. His work has led to the approval of several treatments in kidney cancer such as cabozantinib, avelumab, and others. His work has been published in journals such as the New England Journal of Medicine, Nature, Science, Cancer Cell, Journal of American Medical Association, Journal of Clinical Oncology, Lancet Oncology, Clinical Cancer Research, and many others. He lectures frequently throughout the United States and around the world. He has over 500 PubMed-listed publications and is the lead investigator of multiple national and international phase I-III trials in GU cancers. Dr. Choueiri will bring great insight to the interpretation of the data from MARIO-3 in RCC and the development of next steps.